Drug Pricing: CMS Seeing ‘Too Many Examples’ Of Excessive Increases
Executive Summary
Acting Administrator Slavitt says big prescription drug price increases are a widespread practice and controlling drug costs ‘is likely to be a big priority’ for next head of CMS.
You may also be interested in...
FDA/CMS Collaboration: “Sleeper Group” Goes Public With Call For Real-World Evidence
US FDA, CMS and NIH are hoping to create a “single front door” for research. Article outlining collaboration on real-world evidence suggests one path forward.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.